This product should be administered with care when co-administered with the following drugs.
| Drug Name | Clinical Symptoms/ Measures |
Mechanism/Risk Factor |
| Loop diuretics Ethacrynic acid Furosemide, etc. Thiazide and similar antihypertensive diuretics Trichlormethiazide Chlortalidone, etc. |
Since hypokalaemia (feelings of weakness, muscular weakness, etc.) might develop, adequate measures should be taken with careful observation (including determination of serum potassium level). | These diuretics enhance the potassium excreting effect of glycyrrhizic acid contained in this product, thus tending to decrease serum potassium. |
| Moxifloxacin hydrochloride | Ventricular tachycardia (including torsade de pointes) and QT prolongation may occur. | When serum potassium concentration decreases by the potassium-excreting effect of glycyrrhizic acid contained in this product, ventricular tachycardia (including torsade de pointes) and QT prolongation due to moxifloxacin hydrochloride may occur. |
